ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2018
Evaluation of E. coli inhibition by plain and polymer-coated silver nanoparticles.
Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 67 citations in OpenAlex.
- Recent Advances of Silver Nanoparticles in Wound Healing: Evaluation of In Vivo and In Vitro Studies.International journal of molecular sciences · 2025Review
- Tailoring innovative silver nanoparticles for modern medicine: The importance of size and shape control and functional modifications.Materials today. Bio · 2025Review
- Highlight the role of propolis-pollen-nanoemulsion effect ofOpen veterinary journal · 2025Article
- Green synthesis of silver nanoparticles using Acroptilon repens aqueous extract and their antibacterial efficacy against multidrug-resistant Acinetobacter baumannii.Molecular biology reports · 2024Article
- Microwave-enhanced antibacterial activity of polydopamine-silver hybrid nanoparticles.RSC advances · 2024Article
- Preparation of hybrid particles of Ag nanoparticles and eggshell calcium carbonate and their antimicrobial efficiency against beef-extracted bacteria.Royal Society open science · 2023Article
- Perspectives on Usage of Functional Nanomaterials in Antimicrobial Therapy for Antibiotic-Resistant Bacterial Infections.ACS omega · 2023Review
- Silver nanoparticles with plasma-polymerized hexamethyldisiloxane coating on 3D printed substrates are non-cytotoxic and effective against respiratory pathogens.Frontiers in microbiology · 2023Article
- Silver Nanoparticle-Based Combinations with Antimicrobial Agents against Antimicrobial-Resistant Clinical Isolates.Antibiotics (Basel, Switzerland) · 2022Article
- Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies.Journal of nanobiotechnology · 2022Review
- Urinary Tract Infections Caused by UropathogenicMicroorganisms · 2022Article
- Green Synthesis of Silver Nanoparticles Coated by Water Soluble Chitosan and Its Potency as Non-Alcoholic Hand Sanitizer Formulation.Materials (Basel, Switzerland) · 2022Article
- Nanoparticles of Bioactive Metals/Metal Oxides and Their Nanocomposites with Antibacterial Drugs for Biomedical Applications.Materials (Basel, Switzerland) · 2022Review
- Improved transformation ofBiotechnologia · 2022Article
- Antimicrobial TiOChemical engineering journal (Lausanne, Switzerland : 1996) · 2021Article
- Insights into the metal retention role in the antibacterial behavior of montmorillonite and cellulose tissue-supported copper and silver nanoparticles.RSC advances · 2021Article
- Silver Nanoparticles and Their Antibacterial Applications.International journal of molecular sciences · 2021Review
- Transcriptome Profile Alterations with Carbon Nanotubes, Quantum Dots, and Silver Nanoparticles: A Review.Genes · 2021Review
- Nanomaterials for the Diagnosis and Treatment of Urinary Tract Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections.Nature reviews. Microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Escherichia coli causes various ailments such as septicemia, enteritis, foodborne illnesses, and urinary tract infections which are of concern in the public health field due to antibiotic resistance. Silver nanoparticles (AgNP) are known for their biocompatibility and antibacterial activity, and may prove to be an alternative method of treatment, especially as wound dressings. In this study, we compared the antibacterial efficacy of two polymer-coated silver nanoparticles either containing 10% Ag (Ag 10% + Polymer), or 99% Ag (AgPVP) in relation to plain uncoated silver nanoparticles (AgNP). Atomic force microscopy was used to characterize the nanoparticles, and their antibacterial efficacy was compared by the minimum inhibitory concentration (MIC) and bacterial growth curve assays, followed by molecular studies using scanning electron microscopy (SEM) and (qRT- PCR). AgNP inhibited the growth of E. coli only at 0.621 mg/mL, which was double the concentration required for both coated nanoparticles (0.312 mg/mL). Similarly, bacterial growth was impeded as early as 8 h at 0.156 mg/mL of both coated nanoparticles as compared to 0.312 mg/mL for plain AgNP. SEM data showed that nanoparticles damaged the cell membrane, resulting in bacterial cell lysis, expulsion of cellular contents, and complete disintegration of some cells. The expression of genes associated with the TCA cycle (aceF and frdB) and amino acid metabolism (gadB, metL, argC) were substantially downregulated in E. coli treated with nanoparticles. The reduction in the silver ion (Ag+) concentration of polymer-coated AgNP did not affect their antibacterial efficacy against E. coli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.